Human Epidermal Growth Factor Receptor 2 (her2) - Cancer Science

Relevant Publications

Synthesis and evaluation of antibody-drug conjugates with high drug-to-antibody ratio using dimaleimide-DM1 as a linker- payload.

Issue Release: 2024

Ferroptosis as a promising targeted therapy for triple negative breast cancer.

Issue Release: 2024

Impact of coadministration of proton-pump inhibitors and palbociclib in hormone receptor-positive/HER2-negative advanced breast cancer.

Issue Release: 2024

Real-world Outcomes of Dual HER2 Blockade Therapy in Metastatic HER2-Positive Breast Cancer: from Induction to Maintenance.

Issue Release: 2024

Cubosomes functionalized with antibodies as a potential strategy for the treatment of HER2-positive breast cancer.

Issue Release: 2024

3D layered co-culture model enhances Trastuzumab Deruxtecan sensitivity and reveals the combined effect with G007-LK in HER2-positive non-small cell lung cancer.

Issue Release: 2024

DNAzyme and controllable cholesterol stacking DNA machine integrates dual-target recognition CTCs enable homogeneous liquid biopsy of breast cancer.

Issue Release: 2024

Noninvasive identification of HER2-zero, -low, or -overexpressing breast cancers: Multiparametric MRI-based quantitative characterization in predicting HER2-low status of breast cancer.

Issue Release: 2024

Mechanisms of acquired resistance to HER2-Positive breast cancer therapies induced by HER3: A comprehensive review.

Issue Release: 2024

INPP4B suppresses HER2-induced mesenchymal transition in HER2+ breast cancer and enhances sensitivity to Lapatinib.

Issue Release: 2024

Clinical application of targeted tumour sequencing tests for detecting ERBB2 amplification and optimizing anti-HER2 therapy in gastric cancer.

Issue Release: 2024

Does immunohistochemical marker conversion affect the prognosis in breast cancer patients receiving neoadjuvant chemotherapy?

Issue Release: 2024

Spectrum and characteristics of germline PALB2 pathogenic variants in 1556 early-onset breast cancer patients in China.

Issue Release: 2024

Feasibility of risk assessment for breast cancer molecular subtypes.

Issue Release: 2024

Quality Assurance Model for Breast Cancer Prognostication Using the Modified Magee Equations.

Issue Release: 2024

CDK4/6 inhibitors as adjuvant therapy in early breast cancer? Uncertain benefits, guaranteed harms.

Issue Release: 2024

Attempt to Substitute the Oncotype DX Breast Recurrence Score Test by Histopathological Factors and MUC1 Protein Expression.

Issue Release: 2024

Insights Into the Emerging Entity of HER2-Low Breast Cancer.

Issue Release: 2024

The therapeutic role of γδT cells in TNBC.

Issue Release: 2024

Recent Progress of Multifunctional Molecular Probes for Triple-Negative Breast Cancer Theranostics.

Issue Release: 2024

How Does Bortezomib Work?

Why is Understanding Biological Variability Important?

How Can Healthcare Providers Improve Resource Efficiency?

How is Neurogenic Bladder Related to Cancer?

How Common is Recall in Cancer Screening?

How Can Patients Manage Out-of-Pocket Costs?

How Can the Assay Be Improved?

Why is a Cystoscopy Important in Cancer Diagnosis?

What Can Be Done to Address This Issue?

How Can HLAA Help Cancer Patients with Hearing Loss?

Partnered Content Networks

Relevant Topics